Treatment Options for Protease Inhibitor-exposed Children (NEVEREST-III)

Columbia University

Status and phase: Completed; Phase 3

Conditions: HIV Infections; HIV/AIDS

Treatments: Drug: Efavirenz (EFV); Drug: Stavudine (D4T); Drug: Abacavir (ABC); Drug: Lopinavir/ritonavir (LPV/r)

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT01146873

AAAE1145

R01HD061255 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The investigators hypothesize that switching to a regimen based on efavirenz will be as effective and safe as remaining on a regimen based on Lopinavir/ritonavir for HIV-infected children.

The investigators propose an unblinded randomized clinical trial to evaluate a simplification, protease-inhibitor (PI)-sparing treatment strategy among nevirapine (NVP)-exposed HIV-infected children treated initially with lopinavir/ritonavir (LPV/r). HIV-infected children aged 3-5 years, who have a history of exposure to NVP as part of prevention of mother-to-child HIV transmission (PMTCT), initiated LPV/r-based therapy in the first 36 months of life or who were enrolled on the control arm of Neverest 2 and who are virally suppressed with a viral load < 50 copies/ml will be included. These children will be randomized to either substitute efavirenz (EFV) for LPV/r or to continue on their LPV/r-based regimen. Eight weeks prior to the primary randomization, eligible children will also be randomized to either remain on stavudine (D4T) or switch to abacavir (ABC). Children will be followed with regular viral load and other clinical tests for 48 weeks after the primary randomization. Children in the experimental arm who have breakthrough viremia (-defined as two subsequent viral loads > 1000 copies/ml) on the EFV-based regimen will reinitiate the LPV/r regimen. The primary objective is to test whether the durability of viral suppression is equivalent when children are switched to EFV-based therapy. The primary study endpoint is failure to have HIV RNA < 50 copies/ml and/or confirmed viremia >1000 copies/ml. Secondary aims include comparison of immune preservation, toxicities, selection of resistance mutations, and adherence across the two arms. Antiretroviral drug concentrations and adherence will be investigated as possible explanations for the success and/or failure of this simplification regimen. The overall goal of the study is to contribute to the evidence base to allow expansion of treatment options for HIV-infected children in low resource settings.

Enrollment: 300 patients

Sex: All

Ages: 3+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HIV-infected child 3 to 5 years of age at time of screening for this trial if enrolled from outside or any age if enrolled from control arm of Neverest II.
• Reliable history or documented exposure to NVP used as part of PMTCT
• Initiated antiretroviral therapy with LPV/r at age less than 36 months
• Receiving LPV/r-based ART for at least 12 months
• At least one viral load measurement less than 50 copies/ml conducted as part of screening for the study
• ALT measurement grade I or less (DAIDS Toxicity Tables 2004) (Appendix A). These may be repeated until ALTs normalize if necessary.

Exclusion criteria

• Prior treatment with any NNRTI drug as part of a therapeutic regimen
• Substitution of other NRTI drugs (instead of 3TC and D4T which are the standard first line regimen) will be allowed.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

300 participants in 4 patient groups

Group 1: Lopinavir/ritonavir (LPV/r)

Active Comparator group

Description:

Participants are assigned to remain on their current LPV/r-based antiretroviral regimen. Ritonavir-boosted lopinavir syrup was given twice per day at 230 mg/m\^2 per dose. Children able to swallow tablets were given 1 tablet twice per day (200 mg lopinavir/50 mg ritonavir) if body surface area was less than 0.9m\^2 or 2 tablets twice per day if body surface area was 0.9m\^2 or higher.

Treatment:

Drug: Lopinavir/ritonavir (LPV/r)

Group 2: Efavirenz (EFV)

Experimental group

Description:

Participants are assigned to switch to an EFV-based antiretroviral regimen. Efavirenz was prescribed once daily in the evening at 200 mg for weights of 10 kg to 13.9 kg (22-30 lb) and 300mg for weights of 14 kg to 24.9 kg (31-55 lb). Efavirenz was available in 50-mg and 200-mg capsules. If children were unable to swallow capsules, caregivers were shown how to open the capsules and dissolve the contents in water.

Treatment:

Drug: Efavirenz (EFV)

Group D: Stavudine (D4T)

Active Comparator group

Description:

Children are assigned to remain on their current antiretroviral regimen, which includes D4T. D4T was given at 1 mg/kg twice daily

Treatment:

Drug: Stavudine (D4T)

Group A: Abacavir (ABC)

Experimental group

Description:

Children stop taking D4T and switch to ABC. ABC was given at 8 mg/kg twice daily.

Treatment:

Drug: Abacavir (ABC)